The development of therapeutic and prophylactic HIV vaccines for African countries is urgently needed, but the question of what immunogens to use needs to be answered. One approach is to include HIV envelope immunogens derived from HIV-positive individuals from a geographically concentrated epidemic with more limited viral genetic diversity for a region-based vaccine. To address if there is a basis for a regional selected antibody vaccine, we have screened two regionally separate cohorts from Guinea-Bissau and Denmark for neutralizing antibody activity and antibody-dependent cellular cytotoxicity (ADCC) against local and nonlocal circulating HIV-1 strains. The neutralizing activity did not demonstrate higher potential against local circulating strains according to geography and subtype determination, but the plasma from Danish individuals demonstrated significantly higher inhibitory activity than that from Guinea-Bissau individuals against both local and nonlocal virus strains. Interestingly, an opposite pattern was observed with ADCC activity, where Guinea-Bissau individual plasma demonstrated higher activity than Danish plasma and was specifically against the local circulating subtype. Thus, on basis of samples from these two cohorts, no local-specific neutralizing activity was detected, but a local ADCC response was identified in the Guinea-Bissau samples, suggesting potential use of regional immunogens for an ADCC-inducing vaccine.
Get full access to this article
View all access options for this article.
References
1.
MascolaJR, StieglerG, VanCottTC, et al.: Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med, 2000; 6:207–210.
2.
BabaTW, LiskaV, Hofmann-LehmannR, et al.: Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med, 2000; 6:200–206.
3.
JulienJP, SokD, KhayatR, et al.: Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog, 2013; 9:e1003342.
4.
BinleyJM, LybargerEA, CrooksET, et al.: Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol, 2008; 82:11651–11668.
5.
BinleyJM, WrinT, KorberB, et al.: Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol, 2004; 78:13232–13252.
6.
SimekMD, RidaW, PriddyFH, et al.: Human immunodeficiency virus type 1 elite neutralizers: Individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol, 2009; 83:7337–7348.
7.
van GilsMJ, EulerZ, SchweighardtB, WrinT, SchuitemakerH: Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression. AIDS, 2009; 23:2405–2414.
KwongPD, MascolaJR: Human antibodies that neutralize HIV-1: Identification, structures, and B cell ontogenies. Immunity, 2012; 37:412–425.
10.
BonsignoriM, PollaraJ, MoodyMA, et al.: Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol, 2012; 86:11521–11532.
11.
HaynesBF, GilbertPB, McElrathMJ, et al.: Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med, 2012; 366:1275–1286.
12.
LambotteO, FerrariG, MoogC, et al.: Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS, 2009; 23:897–906.
13.
WrenLH, ChungAW, IsitmanG, et al.: Specific antibody-dependent cellular cytotoxicity responses associated with slow progression of HIV infection. Immunology, 2013; 138:116–123.
14.
PollaraJ, BonsignoriM, MoodyMA, PazgierM, HaynesBF, FerrariG: Epitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responses. Curr HIV Res, 2013; 11:378–387.
15.
PollaraJ, BonsignoriM, MoodyMA, et al.: HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities. J Virol, 2014; 88:7715–7726.
16.
van GilsMJ, SandersRW: Broadly neutralizing antibodies against HIV-1: Templates for a vaccine. Virology, 2013; 435:46–56.
17.
TaylorBS, SobieszczykME, McCutchanFE, HammerSM: The challenge of HIV-1 subtype diversity. N Engl J Med, 2008; 358:1590–1602.
18.
Ndung'uT, WeissRA: On HIV diversity. AIDS, 2012; 26:1255–1260.
19.
Rerks-NgarmS, PitisuttithumP, NitayaphanS, et al.: Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med, 2009; 361:2209–2220.
20.
StephensonKE, BarouchDH: A global approach to HIV-1 vaccine development. Immunol Rev, 2013; 254:295–304.
21.
ChurchyardGJ, MorganC, AdamsE, et al.: A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS One, 2011; 6:e21225.
22.
HammerSM, SobieszczykME, JanesH, et al.: Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med, 2013; 369:2083–2092.
23.
JulienJP, CupoA, SokD, et al.: Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science, 2013; 342:1477–1483.
24.
SandersRW, DerkingR, CupoA, et al.: A next-generation cleaved, soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog, 2013; 9:e1003618.
25.
BorggrenM, VinnerL, AndresenBS, et al.: Optimization of HIV-1 envelope DNA vaccine candidates within three different animal models, Guinea pigs, rabbits and cynomolgus macaques. Vaccines, 2013; 1:305–327.
26.
PalmAA, EsbjornssonJ, ManssonF, et al.: Faster progression to AIDS and AIDS-related death among seroincident individuals infected with recombinant HIV-1 A3/CRF02_AG compared with sub-subtype A3. J Infect Dis, 2013 [Epub ahead of print]; DOI: 10.1093/infdis/jit416.
27.
EsbjornssonJ, MildM, ManssonF, NorrgrenH, MedstrandP: HIV-1 molecular epidemiology in Guinea-Bissau, West Africa: Origin, demography and migrations. PLoS One, 2011; 6:e17025.
28.
AbecasisAB, WensingAM, ParaskevisD, et al.: HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics. Retrovirology, 2013; 10:7.
29.
AudelinAM, CowanSA, ObelN, NielsenC, JorgensenLB, GerstoftJ: Phylogenetics of the Danish HIV epidemic: The role of very late presenters in sustaining the epidemic. J Acquir Immune Defic Syndr, 2013; 62:102–108.
30.
OliveiraI, AndersenA, FurtadoA, et al.: Assessment of simple risk markers for early mortality among HIV-infected patients in Guinea-Bissau: A cohort study. BMJ Open, 2012; 2:e001587.
31.
JespersenS, HongeBL, OliveiraI, et al.: Cohort profile: The Bissau HIV Cohort-a cohort of HIV-1, HIV-2 and co-infected patients. Int J Epidemiol, 2015; 44:756–763.
32.
RomanVR, JensenKJ, JensenSS, et al.: Therapeutic vaccination using cationic liposome-adjuvanted HIV type 1 peptides representing HLA-supertype-restricted subdominant T cell epitopes: Safety, immunogenicity, and feasibility in Guinea-Bissau. AIDS Res Hum Retroviruses, 2013; 29:1504–1512.
33.
KarlssonI, BrandtL, VinnerL, et al.: Adjuvanted HLA-supertype restricted subdominant peptides induce new T-cell immunity during untreated HIV-1-infection. Clin Immunol, 2013; 146:120–130.
34.
TamuraK, PetersonD, PetersonN, StecherG, NeiM, KumarS: MEGA5: Molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol, 2011; 28:2731–2739.
35.
LoleKS, BollingerRC, ParanjapeRS, et al.: Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol, 1999; 73:152–160.
36.
SeamanMS, JanesH, HawkinsN, et al.: Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol, 2010; 84:1439–1452.
37.
GrahamFL, SmileyJ, RussellWC, NairnR: Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol, 1977; 36:59–74.
38.
ConnorRI, ChenBK, ChoeS, LandauNR: Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology, 1995; 206:935–944.
39.
HeJ, ChoeS, WalkerR, Di MarzioP, MorganDO, LandauNR: Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol, 1995; 69:6705–6711.
40.
WeiX, DeckerJM, LiuH, et al.: Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother, 2002; 46:1896–1905.
41.
MontefioriDC. Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol Biol, 2009; 485:395–405.
42.
HeyndrickxL, HeathA, Sheik-KhalilE, et al.: International network for comparison of HIV neutralization assays: The NeutNet report II. PLoS One, 2012; 7:e36438.
43.
JensenSS, HartlingHJ, TingstedtJL, et al.: HIV-specific ADCC improves after antiretroviral therapy and correlates with normalization of the NK cell phenotype. J Acquir Immune Defic Syndr, 2015; 68:103–111.
44.
PollaraJ, HartL, BrewerF, et al.: High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. Cytometry A, 2011; 79:603–612.
45.
TrkolaA, MatthewsJ, GordonC, KetasT, MooreJP: A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor. J Virol, 1999; 73:8966–8974.
46.
MadhaviV, WrenLH, CenterRJ, et al.: Breadth of HIV-1 Env-specific antibody-dependent cellular cytotoxicity: Relevance to global HIV vaccine design. AIDS, 2014; 28:1859–1870.
47.
NimmerjahnF, RavetchJV: Fcgamma receptors as regulators of immune responses. Nat Rev Immunol, 2008; 8:34–47.
48.
JohanssonSE, RollmanE, ChungAW, et al.: NK cell function and antibodies mediating ADCC in HIV-1-infected viremic and controller patients. Viral Immunol, 2011; 24:359–368.
49.
MoorePL, WilliamsonC, MorrisL: Virological features associated with the development of broadly neutralizing antibodies to HIV-1. Trends Microbiol, 2015; 23:204–211.
50.
GrayES, MadigaMC, HermanusT, et al.: The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol, 2011; 85:4828–4840.
51.
SatherDN, ArmannJ, ChingLK, et al.: Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol, 2009; 83:757–769.
52.
MataMM, IwemaJR, DellS, et al.: Comparison of antibodies that mediate HIV type 1 gp120 antibody-dependent cell-mediated cytotoxicity in asymptomatic HIV type 1-positive men and women. AIDS Res Hum Retroviruses, 2014; 30:50–57.
53.
JacobRA, AbrahamsF, TongoM, et al.: Refined identification of neutralization-resistant HIV-1 CRF02_AG viruses. J Virol, 2012; 86:7699–7703.
54.
BrownBK, WieczorekL, Sanders-BuellE, et al.: Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. Virology, 2008; 375:529–538.
55.
MoogC, FleuryHJ, PellegrinI, KirnA, AubertinAM: Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J Virol, 1997; 71:3734–3741.
56.
CorbetS, VinnerL, HougaardDM, et al.: Construction, biological activity, and immunogenicity of synthetic envelope DNA vaccines based on a primary, CCR5-tropic, early HIV type 1 isolate (BX08) with human codons. AIDS Res Hum Retroviruses, 2000; 16:1997–2008.
57.
VinnerL, TherrienD, WeeE, et al.: Immune response in rhesus macaques after mixed modality immunisations with DNA, recombinant adenovirus and recombinant gp120 from human immunodeficiency virus type 1. APMIS, 2006; 114:690–699.
58.
VinnerL, WeeEG, PatelS, et al.: Immunogenicity in Mamu-A*01 rhesus macaques of a CCR5-tropic human immunodeficiency virus type 1 envelope from the primary isolate (Bx08) after synthetic DNA prime and recombinant adenovirus 5 boost. J Gen Virol, 2003; 84(Pt 1):203–213.
59.
HessellAJ, HangartnerL, HunterM, et al.: Fc receptor but not complement binding is important in antibody protection against HIV. Nature, 2007; 449:101–104.
60.
ChungAW, IsitmanG, NavisM, et al.: Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure. Proc Natl Acad Sci U S A, 2011; 108:7505–7510.
61.
Smalls-ManteyA, Doria-RoseN, KleinR, et al.: Antibody-dependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding. J Virol, 2012; 86:8672–8680.
62.
CarrJK, SalminenMO, AlbertJ, et al.: Full genome sequences of human immunodeficiency virus type 1 subtypes G and A/G intersubtype recombinants. Virology, 1998; 247:22–31.
63.
HeyndrickxL, Stewart-JonesG, JanssonM, et al.: Selected HIV-1 Env trimeric formulations act as potent immunogens in a rabbit vaccination model. PLoS One, 2013; 8:e74552.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
